Journal
PHARMACOLOGICAL RESEARCH
Volume 60, Issue 2, Pages 117-125Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2009.03.008
Keywords
Acylethanolamides; Anandamide; Apoptosis; Cannabinoid receptors; Colon cancer; Diarrhoea; Gut; Endocannabinoids; Inflammatory bowel disease; Intestinal motility; Phytocannabinoids; Visceral pain; Fatty acid amide hydrolase; Prostamides; Cannabidiol
Categories
Funding
- PRIN
- Enrico and Enrica Sovena Foundation
Ask authors/readers for more resources
Emerging evidence suggests that cannabinoids may exert beneficial effects in intestinal inflammation and cancer. Adaptive changes of the endocannabinoid system have been observed in intestinal biopsies from patients with inflammatory bowel disease and colon cancer. Studies on epithelial cells have shown that cannabinoids exert antiproliferative, antimetastatic and apoptotic effects as well as reducing cytokine release and promoting wound healing. In vivo, cannabinoids - via direct or indirect activation of CB1 and/or CB2 receptors - exert protective effects in well-established models of intestinal inflammation and colon cancer. Pharmacological elevation of endocannabinoid levels may be a promising strategy to counteract intestinal inflammation and colon cancer. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available